Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01477060
Other study ID # CROLT/02
Secondary ID 2011-000155-16
Status Terminated
Phase Phase 2
First received November 16, 2011
Last updated February 19, 2014
Start date November 2011
Est. completion date December 2013

Study information

Verified date February 2014
Source Fondazione Michelangelo
Contact n/a
Is FDA regulated No
Health authority Italy: Ethics Committee
Study type Interventional

Clinical Trial Summary

Target Population: female patients with HER2-negative, ER and/or PgR positive breast cancer in progression after first-line hormonal therapy.

The study rationale is based on the potentiality of reversing endocrine-resistance by Lapatinib

- Activity on compensatory-adaptive mechanisms of hyperactivity of signals generated by HER2 family

- Modulation of energy balance and signals associated to survival through AMPK activation (via Calmodulin) Metformin

- Indirect mechanism, through reduced insulin receptors and IGFR stimulation, with reduces proliferative effects downstream

- Direct mechanism, through AMPK activation (via LKB1), with reduced protein synthesis (mTOR inhibition) and increased availability of intracellular energy Lapatinib and Metformin

- AMPK "Double"activation, through different potentially additional mechanisms.

- Inhibition of proliferative mechanisms for interference on various intracellular target

- IR (A e/o B); IGFR

- EGFR; HER2

Primary objectives :

1. To assess the rate of patients free from disease progression at 3 months from randomization

Secondary objectives :

1. To assess the overall response rate

2. To assess the duration of response

3. To assess 3-years overall survival rate

4. To assess tolerability of each proposed treatment Female patients with HER2-negative, ER and/or PgR positive breast cancer in progression after first-line hormonal therapy will randomized to receive: hormonal therapy + lapatinib or hormonal therapy + metformin or hormonal therapy + metformin + lapatinib with a ratio 1:1:1.

For each arm of the study the following sample size is required:

- First step: 23 patients, for a total of 69 patients in all 3 arms

- Second step: further 33 patients, for a total of 168 patients in all 3 arms.


Description:

Treatment Plan Patient will continue to be treated with the same hormone therapy at the same dose, route and schedule

Patients will be randomized to receive:

A: Lapatinib, 1250 mg/die, os B: Metformin, 1500 mg/die, os C: Lapatinib + Metformin, 1250 mg+1500 mg/die, os Patients will receive study treatment until disease progression is documented, extraordinary medical circumstances occur, intolerable toxicities occur, or the patient withdraws consent

Statistical consideration Randomization will be stratified according to the site of metastases: visceral versus non-visceral lesions. The primary objective of this study is to evaluate the rate of patients free of disease progression at 3 months from randomization. The final analysis of this objective will be conducted when a total of 168 patients are enrolled across the three arms. This is the number of patients needed for a test with an experiment-wise alpha = 0.05 and power = 80% to show a statistically significant increment of 10% to the rate of patients without disease progression at 3 months, assuming a rate of 5% for treatments without lapatinib and/or metformin (P0=5% and P1=15%). After having accrued a total of 23 evaluable patients in each arm, the trial design can proceed to step 2 randomizing additional patients to each arm only if two or more patients are free of disease progression at 3 months. Otherwise, the study arm with less than expected responses will be discontinued. In the second stage 33 additional patients will be enrolled in each study arm to reach a total of 56 total patients per arm. If less than 6 patients per arm will be free of disease progression then the increment of corresponding treatment will be considered not significant.

Procedures:

The study will consist of a screening period, a treatment period and follow up for survival Screening Phase

Within 4 weeks prior randomization:

A signed written, informed consent will be obtained prior to any study specific assessments are initiated. The following will be performed prior to randomization

- Radiographic complete assessment of disease status (chest Xray; liver ultrasound, bone scan and CT or MR of target lesions and involved sites)

- Hematology and biochemistry

- Pregnancy test for women of child-bearing potential

- Cardiac assessment with ECG, echocardiography or multi-gated scintigraphic scan (MUGA)

- Medical history, physical examination, vital signs, signs and symptoms of breast cancer lesions, weight, height, ECOG performance status

Treatment Phase:

MONTHLY up to 3 months since randomization

- Physical examination, including clinical disease assessment, ECOG performance status, vital signs

- Hematology and biochemistry

- Safety evaluation (i.e. routine collection of adverse events)

- Patient's compliance

- Concomitant therapy

EVERY 3 MONTHS after the first 3 months of treatment until disease progression is documented, intolerable toxicities occur, or the patient withdraws consent:

- Physical examination, including clinical disease assessment, ECOG performance status, vital signs

- Radiographic disease assessment (using the same methods at screening)

- Hematology and biochemistry

- Safety evaluation (i.e. routine collection of adverse events)

- Concomitant therapy

- Patient's compliance

EVERY 6 MONTHS until disease progression is documented, intolerable toxicities occur, or the patient withdraws consent:

- Complete radiographic assessment

- Assessment of the LVEF using the same method at screening

Afterwards:

EVERY 6 MONTHS after disease progression or trial discontinuation due to intolerable toxicities or other reasons. Patients may receive other therapy following study discontinuation. Patients will continue to be followed for survival for a minimum of 3 years.


Recruitment information / eligibility

Status Terminated
Enrollment 32
Est. completion date December 2013
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Female patients with a histologically or cytologically confirmed adenocarcinoma of the breast progressing from prior hormonal therapy

2. Receptor positive disease (ER+ and/or PgR+)

3. HER2 negative

4. Pre- and post-menopausal status

5. Documented disease progression after first-line hormone therapy

6. Age =18 years.

7. Measurable or evaluable metastatic disease

8. Life expectancy > 3 months

9. ECOG Performance Status < 1

10. Adequate bone marrow, liver, and renal function as assessed by the following parameters:

- Hemoglobin > 9.0 g/dl

- Leucocytes count = 3,000/mL

- Absolute neutrophil count (ANC) = 1.500/mL

- Platelet count = 100,000/mL

- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5 x ULN (= 5 x ULN for patients with liver involvement)

- Albumine and total bilirubin = 1.5 x ULN

- Prothrombin Time (PT) < 70 %

- Serum creatinine < 1.4 mg/ml, creatinine clearance > 70 ml/min

11. Normal Respiratory Function and Saturation level = 90%

12. New York Hearth Association (NYHA) Classification = 2 and baseline left ventricular ejection fraction (LVEF)= 50%

13. Patients must be willing and able to sign a written informed consent.

Exclusion Criteria:

1. Previous or concomitant treatment with lapatinib and/or metformin

2. More than one line of prior hormone therapy for metastatic breast cancer.

3. More than two lines of prior chemotherapy for metastatic breast cancer

4. Unique location of disease local-regionally treated (surgery, radiotherapy , other)

5. Disease progression not documented or less than 30%

6. Metastatic disease defined as aggressive at investigator's judgement (e.g. visceral disease more than >1/3 of involved parenchyma, symptomatic disease requiring intensive supportive measures or therapies not allowed by protocol)

7. Patients with brain metastasis

8. Osteosclerotic bone metastasis as unique disease site

9. Pathological tumor markers as unique sign of progressive disease

10. Concomitant treatment with any other anticancer drugs (biphosphonates are permitted)

11. Serious, not solved or unstable toxicity from previous treatment

12. Diabetes mellitus Type I and Type II

13. Renal insufficiency (creatinine = 1.4 mg/ml)

14. Malabsorption syndrome or diseases that significantly may alter gastroenteric functions

15. Other serious illness or medical conditions judged by the investigator to be clinically significant that may adversely affect patient's participation in the trial or interfere with safety profile

16. Active clinically significant or uncontrolled infections (bacterial or viral)

17. Known history of unstable angina (angina symptoms at rest), cardiac ventricular arrhythmias clinically significant, myocardial infarction, stroke or congestive heart failure within 12 months prior to randomization

18. History of lactic acidosis

19. Evidence or symptoms of hepatic insufficiency

20. Chronic alcoholism

21. Concomitant treatment with amiodarone or any other agent that could interfere with study drugs

22. Known or suspected hypersensitivity or allergy to lapatinib, metformin or used excipients

23. Women who are pregnant or lactating

24. History of previous cancer, unless at low risk of relapse per investigator's judgement

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Lapatinib
1250 mg/ die, os
Metformin
1500 mg/die, os

Locations

Country Name City State
Italy Cliniche Gavazzeni S.p.A. - Humanitas Gavazzeni Bergamo BG
Italy Fondazione Poliambulanza Brescia BS
Italy Azienda Ospedaliera "G. Salvini" - P.O. Garbagnate Milanese Garbagnate Milanese MI
Italy Ospedale Civile Di Legnano Legnano MI
Italy Azienda Ospedaliera Ospedale Ca' Granda Milano MI
Italy IRCCS Fondazione San Raffaele Monte Tabor Milano MI
Italy IRCCS Istituto Nazionale dei Tumori Milano MI
Italy Azienda Ospedaliera San Gerardo Monza MB
Italy Fondazione Salvatore Maugeri Clinica del Lavoro e della Riabilitazione - Reparto Riabilitazione Oncologica Pavia PV
Italy Fondazione Salvatore Maugeri Clinica del Lavoro e della Riabilitazione - U.O. Oncologia Pavia PV
Italy Azienda Ospedaliera della Valtellina e della Valchiavenna - P.O. Sondrio Sondrio SO

Sponsors (1)

Lead Sponsor Collaborator
Fondazione Michelangelo

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of patients free from disease progression 3 months from randomization No
Secondary overall response rate 3 years No
Secondary Progression Free Survival 3 years No
Secondary Time to progression 3 years No
Secondary Overall survival To assess 3-years overall survival rate 3 years No
Secondary Number of participants with toxicities as a measure of tolerability of each proposed treatment 3 years Yes
See also
  Status Clinical Trial Phase
Withdrawn NCT04872608 - A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer Phase 1
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Completed NCT02506556 - Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer Phase 2
Recruiting NCT05534438 - A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer Phase 2
Recruiting NCT03368729 - Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer Phase 1/Phase 2
Completed NCT04103853 - Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer Phase 1
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Active, not recruiting NCT03147287 - Palbociclib After CDK and Endocrine Therapy (PACE) Phase 2
Not yet recruiting NCT06062498 - Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer Phase 2
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Recruiting NCT04095390 - A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer Phase 2
Active, not recruiting NCT04432454 - Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Phase 2
Recruiting NCT03323346 - Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer Phase 2
Recruiting NCT05744375 - Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab Phase 2
Completed NCT02924883 - A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy Phase 2
Completed NCT01942135 - Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) Phase 3
Completed NCT01881230 - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Phase 2/Phase 3
Active, not recruiting NCT04448886 - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Phase 2
Completed NCT01401959 - Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy Phase 2
Terminated NCT04720664 - Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer Phase 2